Abstract: This invention discloses a pharmaceutical formulation for nasal administration which contains a pharmaceutically active polypeptide and a method producing the pharmaceutical formulation. The pharmaceutical for formulation comprises: (1) a pharmaceutically active polypeptide, (2) at least one compound selected from the group consisting of taurine, an ester thereof with C1˜6 alcohol, a base metal salt of taurine, hyaluronic acid and a base metal of hyaluronic acid and (3) at least one pharmacologically acceptable additive. It exhibited excellent pharmaceutical activity. No adverse effects such as irration were observed and hence, the present pharmaceutical formulation may suitably be administered nasal mucosa.